Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 4/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8321214 | 0.84 | BRD4 (0.59) | BRD4CHEK1GBA1MAOBHPGD | |
| SCHEMBL8321770 | 0.80 | BRD4 (0.41) | BRD4CHEK1GBA1MAOBCLK1 | |
| SCHEMBL13746140 | 0.80 | BRD4 (0.43) | BRD4CHEK1GBA1MAOBHPGD | |
| SCHEMBL9280138 | 0.79 | PDPK1 (0.49) | BRD4HTR6 | |
| SCHEMBL8298982 | 0.79 | BRD4 (0.41) | BRD4HTR6CYP2C19 | |
| SCHEMBL4199152 | 0.79 | BRD4 (0.41) | BRD4HTR6CYP2C19 | |
| SCHEMBL1487581 | 0.79 | BRD4 (0.43) | BRD4GBA1MAOBHPGDALDH1A1 | |
| SCHEMBL4203368 | 0.78 | BRD4 (0.44) | BRD4ALDH1A1HTR6 | |
| SCHEMBL13745615 | 0.78 | BRD4 (0.42) | BRD4GBA1MAOBHPGDCLK1 | |
| SCHEMBL13620692 | 0.78 | CHEK1 (0.50) | CHEK1MAOBCSNK2A1CLK1CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612086-B2 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7612086-B2 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20070142366-A1 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20070142366-A1 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
| EP-1628975-A2 | JNK INHIBITORS | Eisai Co., Ltd. (JP) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004101565-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004101565-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142366-A1 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | API5, MAP3K5, MAP3K7 | BRD4 469/4885CHEK1 396/4885GBA1 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.